Bioton S.A. Logo

Bioton S.A.

ISIN: PLBIOTN00029 | Ticker: BIO | LEI: 259400I5R1L3OPCGII81
Sector: Health CareSub-Industry: Biotechnology
Country: Poland

About Bioton S.A.

Company Description

BIOTON is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin.

Bioton continuously invests in the development of Polish biotechnology. We are the first and only company in Poland which is able to fully translate its technology into commercial use.

Recombinant human insulin is an efficient and safe therapy for most people suffering from diabetes. We strive to become the provider of complete diabetes care solutions and the preferred choice for patients, doctors and the diabetes community.

Year founded

1989

Served area

Worldwide

Headquarters

Starościńska 5, 02-516 Warszawa – Poland

Financial statements

Download as Excel
Line item in (pln) 02.01.2019 01.01.2020 02.01.2020 01.01.2021 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A 885,079,000.00 N/A 867,107,000.00 N/A 848,127,000.00 N/A 810,326,000.00
Noncurrent Assets N/A 747,620,000.00 N/A 715,819,000.00 N/A 673,399,000.00 N/A 657,255,000.00
Property Plant And Equipment N/A 327,197,000.00 N/A 310,017,000.00 N/A 286,551,000.00 N/A 275,051,000.00
Investment Property N/A 1,357,000.00 N/A 1,357,000.00 N/A 1,357,000.00 N/A 1,357,000.00
Intangible Assets Other Than Goodwill N/A 376,565,000.00 N/A 370,223,000.00 N/A 362,177,000.00 N/A 362,975,000.00
Deferred Tax Assets N/A 35,315,000.00 N/A 27,541,000.00 N/A 5,508,000.00 N/A 2,228,000.00
Current Assets N/A 137,459,000.00 N/A 151,288,000.00 N/A 174,728,000.00 N/A 153,071,000.00
Inventories N/A 79,726,000.00 N/A 90,017,000.00 N/A 125,131,000.00 N/A 111,002,000.00
Trade And Other Current Receivables N/A 48,528,000.00 N/A 37,893,000.00 N/A 39,108,000.00 N/A 31,403,000.00
Current Prepaid Expenses N/A 2,028,000.00 N/A 860,000.00 N/A 1,086,000.00 N/A 1,324,000.00
Current Tax Assets Current N/A N/A N/A 279,000.00 N/A 546,000.00 N/A 3,000.00
Cash and cash equivalents 7,745,000.00 7,177,000.00 7,177,000.00 22,239,000.00 22,239,000.00 8,857,000.00 8,857,000.00 9,339,000.00
Equity And Liabilities N/A 885,079,000.00 N/A 867,107,000.00 N/A 848,127,000.00 N/A 810,326,000.00
Equity 712,792,000.00 582,000,000.00 585,321,000.00 619,645,000.00 619,646,000.00 604,514,000.00 N/A 606,060,000.00
Issued Capital N/A 1,717,284,000.00 N/A 1,717,284,000.00 N/A 1,717,284,000.00 N/A 1,717,284,000.00
Retained Earnings N/A -1,101,878,000.00 N/A -1,067,958,000.00 N/A -1,083,301,000.00 N/A -1,081,880,000.00
Share Premium N/A 57,131,000.00 N/A 57,131,000.00 N/A 57,131,000.00 N/A 57,131,000.00
Equity Attributable To Owners Of Parent N/A 585,320,000.00 N/A 619,645,000.00 N/A 604,514,000.00 N/A 606,060,000.00
Noncurrent Liabilities N/A 102,718,000.00 N/A 90,116,000.00 N/A 77,543,000.00 N/A 63,212,000.00
Noncurrent Provisions For Employee Benefits N/A 2,226,000.00 N/A 1,762,000.00 N/A 1,486,000.00 N/A 1,470,000.00
Noncurrent Accruals And Noncurrent Deferred Income Including Noncurrent Contract Liabilities N/A N/A N/A N/A N/A 36,257,000.00 N/A 32,745,000.00
Deferred Tax Liabilities N/A 162,000.00 N/A 0.00 N/A N/A N/A N/A
Other Noncurrent Financial Liabilities N/A N/A N/A 10,342,000.00 N/A 10,342,000.00 N/A 10,342,000.00
Other Noncurrent Nonfinancial Liabilities N/A 10,382,000.00 N/A 10,342,000.00 N/A N/A N/A N/A
Current Liabilities N/A 197,041,000.00 N/A 157,346,000.00 N/A 166,070,000.00 N/A 141,054,000.00
Current Provisions For Employee Benefits N/A N/A N/A 2,492,000.00 N/A 2,474,000.00 N/A 2,216,000.00
Trade And Other Current Payables N/A 77,693,000.00 N/A 49,971,000.00 N/A 36,932,000.00 N/A 36,095,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A N/A N/A N/A 44,885,000.00 N/A 44,932,000.00
Current Tax Liabilities Current N/A 121,000.00 N/A 5,000.00 N/A 1,162,000.00 N/A 74,000.00
Line item in (pln) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 202,032,000.00 221,788,000.00 163,034,000.00 233,159,000.00
Other Income 3,938,000.00 32,711,000.00 5,946,000.00 4,667,000.00
Profit Loss From Operating Activities 163,543,000.00 48,580,000.00 14,342,000.00 21,258,000.00
Finance Income 9,207,000.00 1,143,000.00 N/A N/A
Finance Costs 7,765,000.00 8,112,000.00 6,011,000.00 16,306,000.00
Profit Loss Before Tax 162,101,000.00 41,611,000.00 8,331,000.00 4,952,000.00
Income Tax Expense Continuing Operations 35,409,000.00 7,691,000.00 5,449,000.00 3,531,000.00
Profit Loss From Continuing Operations -126,692,000.00 33,920,000.00 2,882,000.00 1,421,000.00
Profit (loss) -126,692,000.00 33,920,000.00 2,882,000.00 1,421,000.00
Profit Loss Attributable To Owners Of Parent -126,692,000.00 33,920,000.00 2,882,000.00 1,421,000.00
Line item in (pln) 01.01.2020 02.01.2019 01.01.2021 02.01.2020 01.01.2022 02.01.2021 01.01.2023 02.01.2022
Profit (loss) -126,692,000.00 N/A 33,920,000.00 N/A 2,882,000.00 N/A 1,421,000.00 N/A
Adjustments For Income Tax Expense 620,000.00 N/A 198,000.00 N/A 364,000.00 N/A 292,000.00 N/A
Adjustments For Decrease Increase In Inventories -1,943,000.00 N/A -10,290,000.00 N/A -35,115,000.00 N/A 14,130,000.00 N/A
Adjustments For Decrease Increase In Other Operating Receivables N/A N/A 8,067,000.00 N/A 5,113,000.00 N/A 3,160,000.00 N/A
Adjustments For Increase Decrease In Trade Account Payable 19,470,000.00 N/A -33,218,000.00 N/A N/A N/A N/A N/A
Adjustments For Increase Decrease In Other Operating Payables -1,498,000.00 N/A 8,067,000.00 N/A N/A N/A N/A N/A
Adjustments For Depreciation And Amortisation Expense 32,281,000.00 N/A 31,731,000.00 N/A 31,638,000.00 N/A 34,403,000.00 N/A
Adjustments For Provisions -33,050,000.00 N/A -694,000.00 N/A -128,000.00 N/A 139,000.00 N/A
Adjustments For Unrealised Foreign Exchange Losses Gains 531,000.00 N/A -1,361,000.00 N/A -198,000.00 N/A 3,020,000.00 N/A
Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow 144,311,000.00 N/A -438,000.00 N/A -2,586,000.00 N/A 1,069,000.00 N/A
Interest Paid Classified As Operating Activities N/A N/A N/A N/A 4,785,000.00 N/A 7,270,000.00 N/A
Interest Received Classified As Operating Activities 4,892,000.00 N/A 4,735,000.00 N/A 4,785,000.00 N/A N/A N/A
Income Taxes Paid Refund Classified As Operating Activities 534,000.00 N/A 941,000.00 N/A -636,000.00 N/A -1,470,000.00 N/A
Cash Flows From Used In Operating Activities 46,708,000.00 N/A 41,949,000.00 N/A 5,522,000.00 N/A 56,082,000.00 N/A
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 158,000.00 N/A 14,000.00 N/A 8,608,000.00 N/A 478,000.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities -53,457,000.00 N/A 4,682,000.00 N/A 12,892,000.00 N/A 29,578,000.00 N/A
Cash Flows From Used In Investing Activities -53,802,000.00 N/A -4,684,000.00 N/A -4,284,000.00 N/A -29,100,000.00 N/A
Proceeds From Issuing Shares N/A N/A 311,000.00 N/A N/A N/A N/A N/A
Proceeds From Borrowings Classified As Financing Activities N/A N/A N/A N/A 33,812,000.00 N/A 15,468,000.00 N/A
Repayments Of Borrowings Classified As Financing Activities -33,760,000.00 N/A 18,764,000.00 N/A 43,128,000.00 N/A 32,463,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities -4,736,000.00 N/A 2,486,000.00 N/A 1,525,000.00 N/A 2,706,000.00 N/A
Proceeds From Government Grants Classified As Financing Activities N/A N/A 2,051,000.00 N/A N/A N/A N/A N/A
Interest Paid Classified As Financing Activities -6,412,000.00 N/A 3,315,000.00 N/A 3,780,000.00 N/A 6,798,000.00 N/A
Cash Flows From Used In Financing Activities 6,526,000.00 N/A -22,203,000.00 N/A -14,621,000.00 N/A -26,499,000.00 N/A
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes -568,000.00 N/A 15,062,000.00 N/A -13,383,000.00 N/A 483,000.00 N/A
Cash and cash equivalents 7,177,000.00 7,745,000.00 22,239,000.00 7,177,000.00 8,857,000.00 22,239,000.00 9,339,000.00 8,857,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
POL
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2020

Report
Q1
H1
Q3
FY
Consolidated Report
POL
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

PLBIOTN00029

LEI

259400I5R1L3OPCGII81

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Warsaw Stock Exchange

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.